Loading stock data…
Bausch Health Companies Inc. (BHC)
$6.16-0.27 (-4.20%)
Bausch Health Companies Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bausch Health Companies Inc. in the Healthcare sector is trading at $6.16 with a market capitalization of $2.3B. Wall Street consensus targets $7.50 (5 analysts), implying a +21.8% move over the next 12 months. The stock is currently 23% below its 52-week high of $8.00, remaining 5.1% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.85B↑ | $2.52B↓ | $2.80B↑ | $2.68B↑ | $2.53B |
| Gross Profit | $2.08B↑ | $1.79B↓ | $2.00B↑ | $1.93B↑ | $1.77B |
| Operating Income | $775.00M↑ | $521.00M↓ | $829.00M↑ | $636.00M↑ | $457.00M |
| Net Income | $258.00M↑ | -$1.42B↓ | -$112.00M↓ | $179.00M↑ | $148.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
62.00%
Volume
Today's trading volume
1.40M
Recent News
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Much of this was due to a very well-received quarterly earnings report.
Bausch Health (BHC) Rockets 28% as Q2 Turnaround Fuels Recovery Outlook
Bausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a […]
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and